Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Monday, 2024-02-26. Here's what investors need to know before the announcement.
Analysts estimate that Theravance Biopharma will report an earnings per share (EPS) of $-0.15.
Theravance Biopharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Historical Earnings Performance
Last quarter the company beat EPS by $0.04, which was followed by a 5.34% increase in the share price the next day.
Here's a look at Theravance Biopharma's past performance and the resulting price change:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.21 | -0.16 | -0.26 | -0.17 |
| EPS Actual | -0.17 | -0.13 | -0.24 | -0.21 |
| Price Change % | 5.0% | -1.0% | 0.0% | 2.0% |
Stock Performance
Shares of Theravance Biopharma were trading at $8.675 as of February 22. Over the last 52-week period, shares are down 18.75%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Theravance Biopharma visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.